Brokerages Anticipate Collegium Pharmaceutical Inc (COLL) Will Post Quarterly Sales of $74.28 Million

Equities research analysts expect that Collegium Pharmaceutical Inc (NASDAQ:COLL) will announce $74.28 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Collegium Pharmaceutical’s earnings, with the lowest sales estimate coming in at $71.04 million and the highest estimate coming in at $78.53 million. Collegium Pharmaceutical reported sales of $10.79 million in the same quarter last year, which indicates a positive year-over-year growth rate of 588.4%. The company is expected to issue its next earnings results on Wednesday, March 6th.

On average, analysts expect that Collegium Pharmaceutical will report full year sales of $281.02 million for the current fiscal year, with estimates ranging from $278.03 million to $285.52 million. For the next year, analysts forecast that the company will report sales of $332.99 million, with estimates ranging from $325.78 million to $343.40 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. The company had revenue of $70.20 million during the quarter, compared to analyst estimates of $74.79 million. During the same period in the previous year, the firm posted ($0.45) earnings per share. The company’s revenue was up 485.0% compared to the same quarter last year.

Several research analysts have recently weighed in on COLL shares. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 13th. BidaskClub raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, November 9th. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 target price on shares of Collegium Pharmaceutical in a research note on Thursday, November 8th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.71.

NASDAQ:COLL traded down $0.62 during trading hours on Tuesday, reaching $19.06. The company had a trading volume of 493,743 shares, compared to its average volume of 503,608. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. The company has a market capitalization of $633.69 million, a PE ratio of -7.72 and a beta of 0.29. Collegium Pharmaceutical has a 1-year low of $13.70 and a 1-year high of $29.90.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $16.60, for a total transaction of $415,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 8.1% in the 3rd quarter. Janus Henderson Group PLC now owns 4,119,823 shares of the specialty pharmaceutical company’s stock valued at $60,726,000 after buying an additional 309,477 shares in the last quarter. Macquarie Group Ltd. grew its holdings in Collegium Pharmaceutical by 9.9% in the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock valued at $61,732,000 after buying an additional 233,598 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Collegium Pharmaceutical by 7.0% during the 3rd quarter. BlackRock Inc. now owns 2,409,573 shares of the specialty pharmaceutical company’s stock worth $35,517,000 after purchasing an additional 157,300 shares during the period. Franklin Resources Inc. grew its holdings in shares of Collegium Pharmaceutical by 24.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,759,506 shares of the specialty pharmaceutical company’s stock worth $25,935,000 after purchasing an additional 347,064 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Collegium Pharmaceutical by 9.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,375,709 shares of the specialty pharmaceutical company’s stock worth $20,278,000 after purchasing an additional 113,038 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply